GlassScriptPhysician profile
Michael James Druschel
NPI 1750794731
$14,564.72
in general payments reported to CMS, 2019-2025
15 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.44 · 2020: $2,028 · 2022: $7,713 · 2023: $66.97 · 2024: $4,216 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,299 · Food and Beverage: $360 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,299.00 |
| Food and Beverage | $359.51 |
| Education | $132.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Butterfly Network, INC. | $14,027.00 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $160.06 | 2024 | |
| Amgen INC. | $89.94 | 2024-2025 | Evenity, Prolia |
| Novo Nordisk INC | $75.86 | 2019-2025 | Wegovy |
| Pfizer INC. | $41.12 | 2023 | |
| Genzyme Corporation | $23.00 | 2024 | |
| Exact Sciences Corporation | $22.93 | 2024 | Cologuard Collection Kit |
| Bioventus LLC | $19.67 | 2025 | Xcell |
| Alkermes, INC. | $18.46 | 2025 | Vivitrol |
| Phadia US INC. | $16.80 | 2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $16.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.05 | 2023 | Spravato |
| Lilly USA, LLC | $12.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.80 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Druschel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.